Mogamulizumab companion diagnostics - Kyowa Medex

Drug Profile

Mogamulizumab companion diagnostics - Kyowa Medex

Alternative Names: Poteligeo Test FCM; Poteligeo Test IHC

Latest Information Update: 16 May 2012

Price : $50

At a glance

  • Originator Kyowa Medex
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed T cell lymphoma

Most Recent Events

  • 08 May 2012 Launched for T-cell lymphoma (diagnosis) in Japan (unspecified route)
  • 02 Mar 2012 Registered for T-cell lymphoma (diagnosis) in Japan
  • 26 Apr 2011 Preregistration for T-cell lymphoma (diagnosis) in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top